Ironwood Pharmaceuticals, Inc.
NASDAQ:IRWDDrug Manufacturers - Specialty & Generic
+$0.01 today
- Market cap
- $791.33M
- Beta
- 0.24
- P/E (TTM)
- 5.6
- EPS (TTM)
- $0.63
Volume 2.22M
Average 2.35M
IRWD Change in Working Capital
Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.
Ironwood Pharmaceuticals, Inc.NASDAQ: IRWD
Change in Working Capital · Q1 FY2026 · quarter ended Mar 2026
Change in working capital turns negative
Q1 FY2026 change in working capital was -$59.81M, compared with $50.08M a year earlier. Trailing-twelve-month change in working capital was -$70.23M. Over 3 fiscal years it compounded at +141.4% a year.
Context
- Change in working capital amounted to 13.4% of revenue in FY2025, up 13.2 pp from a year earlier.
- Change in working capital increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly change in working capital holds near -$59.81M or moves back toward the trailing-twelve-month quarterly average of -$17.56M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Change in Working Capital history
USD · from the cash flow
- Latest · FY2025
- 39.65M USD
- Year-over-year change
- +5265.4%
- 4-year CAGR
- +22.3%
| Period | Period end | Change in Working Capital | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 39.65M | +5265.4% |
| FY2024 | 2024-12-31 | 739K | -93.4% |
| FY2023 | 2023-12-31 | 11.28M | +300.0% |
| FY2022 | 2022-12-31 | 2.82M | -84.1% |
| FY2021 | 2021-12-31 | 17.73M | — |
Change in Working Capital vs competitors
How IRWD compares with its peers on the latest reported figures
- IRWD's LTM Mar 2026 change in working capital of $70.23M is the largest of the 3 companies compared; the peer median is $15.21M.
- Its year-over-year change of -507.4% is the lowest of 3, against a peer median of -81.2%.
- Change in working capital amounts to 19.4% of revenue for IRWD, versus a peer median of 4.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $70.23M | -507.4% | +141.4% | 19.4% | |
| LTM Mar 2026 | $28.23M | -31.7% | +17.0% | 6.6% | |
| LTM Sep 2026 | $2.19M | -130.6% | +2.5% | 2.4% | |
| Peer median (excluding IRWD) | $15.21M | -81.2% | +9.8% | 4.5% | |
Competitors are the stored peer set for IRWD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 528.45M | 175.07M | (1B) | 880K | 24.02M |
| Depreciation & Amortization | 1.5M | 1.42M | 1.58M | 2.01M | 1.88M |
| Deferred Income Tax | (333.29M) | 65.74M | 72.64M | 68.09M | 40.8M |
| Stock-Based Compensation | 22.28M | 27.05M | 32.01M | 29.85M | 17.25M |
| Change in Working Capital | 17.73M | 2.82M | 11.28M | 739K | 39.65M |
| Accounts Receivables | 7.71M | 7.99M | 924K | 47.24M | 35.15M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (2.64M) | (8.12M) | 12.38M | (20.21M) | 6.2M |
| Other Working Capital | 12.66M | 2.94M | (2.03M) | (26.29M) | (1.7M) |
| Other Non-Cash Items | 25.23M | 1.67M | 1.07B | 1.98M | 3.45M |
| Operating Cash Flow | 261.9M | 273.76M | 183.43M | 103.55M | 127.04M |
| Capital Expenditures | (265K) | (136K) | (273K) | (142K) | (34K) |
| Acquisitions (Net) | 0 | 0 | (1.03B) | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (265K) | (136K) | (1.03B) | (142K) | (34K) |
| Debt Repayment | 0 | (120.7M) | 300M | (115M) | 0 |
| Common Stock Issued | 19.58M | 9.54M | 6.36M | 11.01M | 216K |
| Common Stock Repurchased | (24.13M) | (126.39M) | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 19.58M | 9.54M | (29.2M) | (2.98M) | 0 |
| Financing Cash Flow | (4.55M) | (237.55M) | 277.16M | (106.97M) | 216K |
| Effect of Forex Changes | 0 | 0 | (53K) | (32K) | (329K) |
| Net Change in Cash | 257.08M | 36.07M | (565.78M) | (3.6M) | 126.9M |
| Free Cash Flow | 261.63M | 273.63M | 183.15M | 103.41M | 127.01M |
Ironwood Pharmaceuticals, Inc.
NASDAQ:IRWD
Intrinsic Alpha fair value
Locked
Current Price
$4.78
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.